Showing 71-80 of 9431 results for "".
- Farming-Associated Maternal Microbiome Linked With Lower Early Childhood Atopic Diseasehttps://practicaldermatology.com/news/study-farming-associated-maternal-microbiome-linked-with-lower-early-childhood-atopic-disease/2487882/A maternal gut microbiome shaped by a traditional farming lifestyle may help explain the protective effect of prenatal farm exposure against atopic disease in children, according to new research published in Allergy.
- Study: Anumigilimab Well Tolerated in HS and Palmoplantar Pustulosishttps://practicaldermatology.com/news/study-anumigilimab-well-tolerated-in-hs-and-palmoplantar-pustulosis/2487876/Anumigilimab was generally well tolerated in patients with hidradenitis suppurativa (HS) or palmoplantar pustulosis (PPP), while providing preliminary signals of clinical activity in both neutrophil-driven inflammatory skin diseases, results from a Phase 1b study
- Imaging-Guided Tape Stripping Standardizes Molecular Profiling in Pediatric Atopic Dermatitishttps://practicaldermatology.com/news/imaging-guided-tape-stripping-standardizes-molecular-profiling-in-pediatric-atopic-dermatitis/2487887/A minimally invasive, imaging-guided tape-stripping technique may provide a standardized method for molecular profiling and treatment monitoring in pediatric atopic dermatitis (AD), according to findings published online ahead of print in the
- Oral Vitamin D Associated With Faster Recovery From Cancer Therapy Skin Toxicitieshttps://practicaldermatology.com/news/oral-vitamin-d-associated-with-faster-recovery-from-cancer-therapy-skin-toxicities/2487854/High-dose oral vitamin D may offer a promising supportive care option for patients experiencing chemotherapy- and radiation-induced skin toxicities, according to a multicenter case series in JAMA Dermatology.
- American Pharmacists Association Urges FDA to Put Patient Safety First in Peptide Reviewhttps://practicaldermatology.com/news/apha-urges-fda-to-put-patient-safety-first-in-peptide-review/2487836/The American Pharmacists Association (APhA) is urging the US Food and Drug Administration (FDA) to prioritize patient safety, scientific evidence, and regulatory oversight in its decision-making process, according to
- Zasocitinib Demonstrates Strong Week 16 Responses Across High-Impact Psoriasis Siteshttps://practicaldermatology.com/news/zasocitinib-demonstrates-strong-week-16-responses-across-high-impact-psoriasis-sites/2487716/Takeda announced new secondary analyses from its pivotal Phase 3 LATITUDE PsO 3001 and 3002 trials showing that the investigational oral TYK2 inhibitor zasocitinib (TAK-279) achieved high rates of skin clearance in adults with moderate-to-severe plaque psoriasis a
- High-Dose Vitamin D May Ease Chemotherapy- and Radiation-Related Skin Toxicities: Analysishttps://practicaldermatology.com/news/high-dose-vitamin-d-may-ease-chemotherapy-and-radiation-related-skin-toxicities/2487809/High-dose oral vitamin D may offer an option for patients experiencing chemotherapy- and radiation-induced skin toxicities, according to a multicenter case series published in JAMA Dermatology.
- ctDNA Outperforms MCPyV Antibody Testing for Merkel Cell Carcinoma Surveillancehttps://practicaldermatology.com/news/ctdna-outperforms-mcpyv-antibody-testing-for-merkel-cell-carcinoma-surveillance/2487805/Circulating tumor DNA (ctDNA) may provide a more accurate method for detecting recurrence of Merkel cell carcinoma (MCC) than the currently available Merkel cell polyomavirus (MCPyV) oncoprotein antibody test, according to results from a multicenter US cohort study
- New Data Support 24-Week Abrocitinib Tapering in Controlled ADhttps://practicaldermatology.com/news/new-data-support-24-week-abrocitinib-tapering-in-controlled-ad/2487773/New data published in the Journal of the American Academy of Dermatology suggests tapering abrocitinib may be a feasible strategy for patients with moderate-to-severe atopic dermatitis (AD) who have achieved an adequate clin
- Report: Dermatology M&A Momentum Sets Sights on Independent Practiceshttps://practicaldermatology.com/news/dermatology-ma-momentum-continues-as-buyers-chase-independent-practices/2487714/Private equity investment in dermatology continues at a rapid pace in 2026, with buyer demand remaining strong despite more than a decade of consolidation across the specialty, according to a new market update from Physician Growth Partners.